title: Intracellular scavenging activity of Trolox (6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid) in the fission yeast, Schizosaccharomyces pombe.
abstract: The ability of Trolox (6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid), a water-soluble vitamin E analogue, to prevent oxidative damages is well characterized, but the mechanisms underlying it remain unclear. The protective effect of Trolox pre-treatment on H(2)O(2)-induced toxicity might be attributed to the decreased cellular permeability to H(2)O(2) or in vitro scavenging activity of Trolox, induction of antioxidant enzymes or the direct scavenging activity of Trolox. The results obtained rule out the first and second possibilities and intracellular scavenging activity was found to be the mechanism whereby Trolox confers protection. This was confirmed by measuring protein oxidation (levels), and the observed decrease in proteasomal activity indicated that the decrease in protein carbonyls was due to Trolox scavenging activity rather than proteasome activation. In conclusion, the intracellular scavenging activity of Trolox is a key protective mechanism against H(2)O(2). These findings obtained in Schizosaccharomyces pombe, a good model organism for eukaryotic cells, can be used as standard protocols for investigating the antioxidant activity of pure or complex potential antioxidants.
authors.affiliation: Department of Biochemistry, Upper Nile University, P.O. Box 1660 Khartoum, Sudan.
authors.forename: Ismail
authors.initials: I
authors.lastname: Hamad
authors.forename: Nazlι
authors.initials: N
authors.lastname: Arda
authors.forename: Murat
authors.initials: M
authors.lastname: Pekmez
authors.forename: Semian
authors.initials: S
authors.lastname: Karaer
authors.forename: Güler
authors.initials: G
authors.lastname: Temizkan
references.citation: Yeast. 2006 Feb;23(3):173-83
references.pmid: 16498704
references.citation: Environ Toxicol Pharmacol. 2002 Jul;11(3-4):321-33
references.pmid: 21782615
references.citation: Mol Aspects Med. 2003 Aug-Oct;24(4-5):195-204
references.pmid: 12892997
references.citation: J Immunol Methods. 1980;38(1-2):161-70
references.pmid: 6778929
references.citation: Nutr Rev. 1997 Jan;55(1 Pt 2):S44-9; discussion S49-52
references.pmid: 9155225
references.citation: Mutat Res. 2001 Sep 20;496(1-2):105-15
references.pmid: 11551486
references.citation: Biochim Biophys Acta. 2005 Jan 17;1703(2):203-12
references.pmid: 15680228
references.citation: Free Radic Biol Med. 2001 Feb 15;30(4):425-32
references.pmid: 11182298
references.citation: Annu Rev Biochem. 1989;58:79-110
references.pmid: 2673022
references.citation: Anticancer Res. 1997 Jul-Aug;17(4A):2459-63
references.pmid: 9252663
references.citation: FEMS Microbiol Lett. 2000 Apr 1;185(1):65-70
references.pmid: 10731608
references.citation: Arch Biochem Biophys. 2000 May 1;377(1):65-8
references.pmid: 10775442
references.citation: J Mol Med (Berl). 2009 May;87(5):515-22
references.pmid: 19255735
references.citation: Cell Biol Int. 2005 Jan;29(1):57-63
references.pmid: 15763500
references.citation: Ann N Y Acad Sci. 2001 Apr;928:22-38
references.pmid: 11795513
references.citation: Arch Toxicol. 1996;71(1-2):20-4
references.pmid: 9010581
references.citation: FASEB J. 1999 Jul;13(10):1145-55
references.pmid: 10385606
references.citation: Biochimie. 2001 Mar-Apr;83(3-4):301-10
references.pmid: 11295490
references.citation: Methods Mol Biol. 2000;99:49-60
references.pmid: 10909076
references.citation: Mol Aspects Med. 2001 Aug-Oct;22(4-5):217-46
references.pmid: 11679167
references.citation: Arch Biochem Biophys. 2002 Aug 15;404(2):279-84
references.pmid: 12147266
references.citation: Clin Chim Acta. 2003 Mar;329(1-2):23-38
references.pmid: 12589963
references.citation: Drug Metab Rev. 2000 Aug-Nov;32(3-4):307-26
references.pmid: 11139131